AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 161 min read$PGNY

Cummings Melissa B sold $53K of PGNY

Cummings Melissa B (Chief Operating Officer) sold 1,879 shares of Progyny, Inc. (PGNY) at $28.00 on 2026-10-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cummings Melissa B
Published Oct 16, 2026, 8:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PGNY
Bearish
medium confidence
Mentioned
$PGNY
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGNYBearishLow
01

Why it matters

The disclosed sale is small and unlikely to affect price materially, but it adds to the transparency of insider activity.

02

Market read

A routine insider sale with limited market impact; primarily of interest to compliance and monitoring teams.

03

What to watch

Potential upcoming corporate actions or earnings that could make the sale more significant if viewed in context.

Relevance 2/10Novelty 2/10Timing: post‑market filing on 2026‑10‑16

Background

Progyny is a provider of fertility benefits; insider transactions are regularly disclosed via Form 4.

Company-level read

Ticker impact

$PGNYBearishMedium confidence
Context

Form 4 filing shows COO Melissa Cummings sold 1,879 shares for $52,612, reducing her stake to 66,496 shares.

Expected impact

likely modest pressure as the market prices in the insider sale

Evidence & confidence

A 10b5‑1 planned sale by a senior officer signals a neutral to slightly bearish signal, but the amount ($53K) is too small to move the stock significantly.

Market effects

Sector

Minimal impact on the broader fertility benefits sector; no material change in industry dynamics.

Regional

Limited to U.S. investors tracking PGNY; no regional ripple effect.

Global

None

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals, so traders might ignore it.

Key entities

  • Company
    Progyny, Inc.

    US‑listed provider of fertility benefits (ticker PGNY).

  • Person
    Melissa Cummings

    Chief Operating Officer of Progyny who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PGNY insider trading history →

Related articles

SEP 10
$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.

tradingview.com3 min
SEP 8
$PGNYMedAI 8/10

Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks

Cencora (COR) is down 6.7% since reporting Q2 earnings, trading at $97.38. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, dropping 14.1% to $25.94. Humana (HUM) reported $40.87B revenue, up 26.2% YoY, beating estimates, and rose 5% to $407.96. Cigna (CI) reported $71.56B revenue, up 6.6% YoY, beating estimates, but fell 4% to $284.64.

yahoo.com3 min
SEP 8
$PGNYMed

Progyny at Wells Fargo healthcare conference: growth runway stays wide

Progyny (PGNY) presented at the Wells Fargo Healthcare Conference, noting seasonal August softness but expecting a September recovery. The company serves 7.2M lives, with a large addressable market. It adjusted 2024 guidance downward but emphasized long-term growth, new product lines, and strong cash flow. Management highlighted Progyny's leading position in fertility benefits and expansion into women's health. The stock is trading below its Fair Value, with a PEG ratio of 0.46, according to Inv

investing.com2 min